Zurück zu den Rankings

Cellebrite DI Ltd. (CLBT)

NEUTRAL
TechnologySoftware - InfrastructureIsrael

Fundamental

68

Kurs

$11.29

Marktkapitalisierung

$2.84B

Teil 1 · Was das Unternehmen wert ist

Übersicht

Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilanz & Liquidität

Umsatz

$496M

Letzte 12 Monate (bis 31.3.2026)

Nettogewinn

$72M

Letzte 12 Monate (bis 31.3.2026)

Freier Cashflow

$125M

Gesamtes Eigenkapital

$538M

Gesamtverbindlichkeiten

$23M

Current Ratio

1.62

Zinsdeckungsgrad

-

Schulden/EBITDA

0.30

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Unterbewertet

Innerer Wert

$19.57

Aktueller Kurs

$11.29

Sicherheitsmarge

+42.3%

Innerer-Wert-Spanne

$12.72 - $26.42

Bewertungsmethoden

Analyst Target:$15.36
DCF:$33.82
PE-based:$5.45
Graham Growth:$11.84
EPV:$1.86
Analystenkonsens:Starker Kauf (14B / 1H / 0S)
Letzte Gewinnüberraschung:-2.57%

Bewertungskennzahlen

P/E-Verhältnis

49.22

ROE

12.4%

P/B-Verhältnis

5.27

P/FCF

22.72

Bruttomarge

83.0%

ROIC

3.8%

Rentabilitäts-Radar

Value Creation (Economic Moat)

ROIC

3.8%

WACC

10.6%

ROIC − WACC

-6.7 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamentalanalyse-Kriterien

Bestanden (13)

  • Gross Margin 83.0%
  • P/FCF 22.72
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • ROE 15.5%
  • Revenue Growth 5Y 19.5%
  • Analyst Consensus 93% Buy
  • Earnings Surprise avg 6.8%
  • PEG Ratio 0.63
  • Earnings Quality (OCF/NI) 2.01
  • Net Margin Trend 16.5% vs -70.5%

Nicht bestanden (6)

  • Price CAGR 0.81%
  • ROIC 3.8%
  • P/B Ratio 5.27
  • CapEx intensity
  • DCF valuation (Overvalued)
  • Piotroski F-Score 2/9

Nicht verfügbar (8)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Share Dilution (missing shares data)

Piotroski F-Score

2/9

Ernsthafte finanzielle Bedenken

score
criteria

Gewinnqualität

2.01

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

-

Aktienrückkäufe. Aktionärsfreundlich

Unternehmensführung

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Latest News

Recent headlines for CLBT, sourced from Markets Gazette.

No recent news for CLBT.